Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Inpatient Payment, Medicare Contractor Reforms Pass With Drug Bill

This article was originally published in The Gray Sheet

Executive Summary

The Senate will take up Medicare contractor and inpatient prospective payment reform proposals within the "Medicare Modernization and Prescription Drug Act" of 2002 (HR 4954) after the July 4 recess

You may also be interested in...



IPPS New Technology Add-On Payment Rate Sufficient – MedPAC Report

CMS should continue to apply strict criteria for new technologies to qualify for "add-on" payments under the hospital inpatient prospective payment system, according to 1MedPAC's March 2003 report

IPPS New Technology Add-On Payment Rate Sufficient – MedPAC Report

CMS should continue to apply strict criteria for new technologies to qualify for "add-on" payments under the hospital inpatient prospective payment system, according to 1MedPAC's March 2003 report

Medicare contractor reform

CMS Administrator Tom Scully and Douglas Wood, MD, chairman of the Secretary's Advisory Committee on Regulatory Reform, will testify Feb. 13 at House Ways & Means/Health Subcommittee hearing on the "Medicare Regulatory and Contracting Reform Act" of 2001 (HR 2768). Provisions were included in Medicare legislation (HR 4954) passed by the House last June (1"The Gray Sheet" June 24, 2002, p. 5). Separately, the House Energy & Commerce Committee will convene Feb. 12 to evaluate the Bush Administration's FY 2004 health care priorities...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel